As an industry-university joint venture of Hitachi High Technology Division and Tohoku University Institute of Development, Aging and Cancer, NeU is introducing a unique brain activity measuring device for individual use. Venture Valuation (VV) interviewed, Kiyoshi Hasegawa, CEO. Read the interview Would you like to be notified about new interviews, reports and other valuable content … Continue reading Interviews with leading Life Sciences companies: NeU Corporation
Zurich 03 March 2020 Last month Biotechgate/Venture Valuation entered a partnership with BioRN, the science and industry cluster of the Rhine-Main-Neckar region, with the goal to develop and run a publicly accessible directory of companies located in the region. The Directory has just been launched and is accessible for free on BioRN’s website. While it … Continue reading The Launch of the Rhine-Main-Neckar Directory
Founded by an accomplished gastroenterologist, AI Medical Service is determined to contribute to the detection of early cancer in the digestive tract by leveraging a CNN deep learning algorithm. Venture Valuation (VV) interviewed Tomohiro Tada, Founder and CEO. Read the interview Would you like to be notified about new interviews, reports and other valuable content … Continue reading Interviews with leading Life Sciences companies: AI Medical Service Inc.
JPM Conference, San Francisco, Jan 2020, 26 pages Company Valuation for Fundraising Presentation
Founded by four experts in laser physics, medical image analysis, and cranio-maxillofacial surgery, AOT is reinventing the bone surgery field with laser osteotomy technology: CARLO® (Cold Ablation Robotguided Laser Osteotome).
Australia Biotech Invest & Partnering 2019, Melbourne, Oct 2019, 15 pages Deal and Product Valuations
It is no surprise that most biotech investors are based in the US. But, do they invest exclusively in American companies? Read the report Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?
Applying intelligently glycemic control and a systematic route through the BBB (blood-brain barrier) to effectively reach neurons. Venture Valuation (VV) interviewed the CEO, Mariko Tosu, PhD
RESI Conference, Philadelphia, Jun 2019, 26 pages Company Valuation for Fundraising Presentation
ITO has developed, since its inception in 1916, high-end professional use therapeutic modalities as well as innovative personal use devices. Venture Valuation (VV) interviewed the COO, Mayuko Ito, great-granddaughter of the founder Kenji Ito.
